<DOC>
	<DOCNO>NCT00824408</DOCNO>
	<brief_summary>The trial objective evaluate whether BI 6727 monotherapy combination pemetrexed may effective treatment advance metastatic NSCLC patient relapse failed first-line platinum base therapy . The secondary objective identify acceptable dose BI 6727 combination pemetrexed characterize pharmacokinetic profile BI 6727 alone . Arm A , BI6727 monotherapy arm close recruitment .</brief_summary>
	<brief_title>Trial BI 6727 ( Volasertib ) Monotherapy BI 6727 Combination With Pemetrexed Compared Pemetrexed Monotherapy Advanced NSCLC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Inclusion criterion : 1 . Pathologic cytologic confirm diagnosis NSCLC 2 . Recurrent , advance metastatic NSCLC progress follow one prior platinum base chemotherapy regimen ( count adjuvant neoadjuvant chemotherapy complete 12 month prior platinum base therapy ) 3 . Patients eligible pemetrexed second line chemotherapy 4 . Measurable disease one technique ( CT , MRI ) accord RECIST 5 . Patients age 18 year old 6 . Life expectancy least three ( 3 ) month 7 . Eastern Cooperative Oncology Group ( ECOG ) performance Score 02 8 . Written inform consent consistent ICHGCP guideline local legislation Exclusion criterion : 1 . Treatment investigational drug another clinical study within past 28 day prior start therapy concomitantly study 2 . Anticancer therapy NSCLC ( except radiotherapy palliative reason ) within past 28 day prior Treatment Day 1 Cycle 1 trial 3 . Any persist toxicity deem clinically significant previous therapy 4 . Patients receive one prior chemotherapy regimen advance disease ( include prior adjuvant therapy ) . Patients may receive prior epidermal growth factor receptor tyrosine kinase inhibitor . 5 . Patients unwilling unable take folic acid vitamin B12 supplementation 6 . Active brain metastasis ( stable &lt; 28 day , symptomatic , require concurrent steroid ) . Patients receive prior whole brain irradiation whose brain metastases stable accord criterion exclude . 7 . Other active malignancy diagnose within past 3 year ( non melanomatous skin cancer cervical intraepithelial neoplasia ) 8 . Concomitant intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness social situation would limit compliance trial requirement consider relevant evaluation efficacy safety trial drug 9 . Patients unable unwilling interrupt concomitant administration NSAIDS 5 day prior , day 2 day administration pemetrexed , exception lose dose aspirin 81mg daily 10 . Patients receive prior therapy pemetrexed 11 . Absolute neutrophil count ( ANC ) less 1,500/mm3 12 . Platelet count less 100,000/mm3 13 . Hemoglobin &lt; 90g/L 14 . Total bilirubin &gt; 26µmol/L 15 . Alanine amino transferase ( ALT ) and/or aspartate amino transferase ( AST ) less 2.5 X ULN , except case know liver metastasis maximum 5 X ULN acceptable 16 . Serum creatinine level &gt; 133µmol/L and/or creatinine clearance ( measure calculate ) &lt; 45 ml/min 17 . Clinically relevant QTc prolongation 18 . Women men sexually active unwilling use medically acceptable method contraception 19 . Pregnancy breast feed 20 . Known suspect active alcohol drug abuse 21 . Patients unable comply protocol 22 . Any known hypersensitivity trial drug excipients 23 . Patients NSCLC confirm Squamous histology</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>